There is limited clinical trial evidence to support the use of STAT3 inhibitors as a breast cancer therapeutic, although one current early-phase trial is currently evaluating the efficacy of an oral STAT3 inhibitor TTI-101 [122] for a range of late-stage cancers including breast cancer (NCT03195699). This evidence concerns the gene STAT3 and breast carcinoma.